Literature DB >> 32502492

Inhibition of RAGE by FPS-ZM1 alleviates renal injury in spontaneously hypertensive rats.

Yu Liu1, Wenzhi Shen1, Qi Chen2, Qingxin Cao3, Wencheng Di1, Rongfang Lan1, Zheng Chen1, Jian Bai1, Zhonglin Han1, Wei Xu4.   

Abstract

The current study was designed to examine the protection of RAGE-specific inhibitor FPS-ZM1 against renal injury in spontaneously hypertensive rats (SHR) and investigate the underlying mechanism. The adult male SHR were treated with FPS-ZM1 via oral gavages for 12 weeks, and age-matched male Wistar-Kyoto rats (WKY) were used as control. Treatment of SHR with FPS-ZM1 slightly reduced blood pressure, and significantly improved baroreflex sensitivity in SHR. Treatment of SHR with FPS-ZM1 improved renal function, evidenced by increased glomerular filtration rate and renal blood flow, and reduced plasma creatinine, blood urea nitrogen and urine albumin excretion rate. Histology results revealed that treatment of SHR with FPS-ZM1 alleviated renal injury and reduced tubulointerstitial fibrosis. Treatment of SHR with FPS-ZM1 suppressed activation of NF-κB and reduced expression of pro-inflammatory cytokines including Tnf, Il6, and Il1b. Treatment of SHR with FPS-ZM1 abated oxidative stress and downregulated mRNA levels of components of NADPH oxidase (Nox) including Cyba, Nox1, Nox2, Nox4 and Ncf1 in kidneys. In addition, treatment of SHR with FPS-ZM1 reduced renal AngII levels, downregulated mRNA expression of Ace and upregulated expression of Agtr2. In conclusion, treatment with FPS-ZM1 alleviated hypertension-related renal dysfunction, possibly by suppressing NF-κB-mediated inflammation, abating Nox-mediated oxidative stress, and improving local renal renin-angiotensin system (RAS).
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FPS-ZM1; Hypertension; Inflammation; Kidney; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32502492     DOI: 10.1016/j.ejphar.2020.173228

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  EPA-Enriched Phospholipids Alleviate Renal Interstitial Fibrosis in Spontaneously Hypertensive Rats by Regulating TGF-β Signaling Pathways.

Authors:  Hao-Hao Shi; Ling-Yu Zhang; Li-Pin Chen; Jin-Yue Yang; Cheng-Cheng Wang; Chang-Hu Xue; Yu-Ming Wang; Tian-Tian Zhang
Journal:  Mar Drugs       Date:  2022-02-19       Impact factor: 5.118

Review 2.  Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.

Authors:  Sara Chiappalupi; Laura Salvadori; Aleksandra Vukasinovic; Rosario Donato; Guglielmo Sorci; Francesca Riuzzi
Journal:  Life Sci       Date:  2021-02-23       Impact factor: 5.037

3.  Attenuating Effects of Dieckol on Hypertensive Nephropathy in Spontaneously Hypertensive Rats.

Authors:  Myeongjoo Son; Seyeon Oh; Junwon Choi; Ji Tae Jang; Kuk Hui Son; Kyunghee Byun
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

4.  Anti-high-mobility group box-1 (HMGB1) mediates the apoptosis of alveolar epithelial cells (AEC) by receptor of advanced glycation end-products (RAGE)/c-Jun N-terminal kinase (JNK) pathway in the rats of crush injuries.

Authors:  Bin-Fei Zhang; Wei Song; Jun Wang; Peng-Fei Wen; Yu-Min Zhang
Journal:  J Orthop Surg Res       Date:  2022-01-15       Impact factor: 2.359

5.  Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice.

Authors:  Forrest Jessop; Benjamin Schwarz; Dana Scott; Lydia M Roberts; Eric Bohrnsen; John R Hoidal; Catharine M Bosio
Journal:  JCI Insight       Date:  2022-01-25

Review 6.  Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors.

Authors:  Harbinder Singh; Devendra K Agrawal
Journal:  Drug Dev Res       Date:  2022-07-04       Impact factor: 5.004

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.